Cervical cancer is not a new phenomenon. In the past Cervical Cancer has been discussed, seen and examined as part of women’s history- the medical and gynaecological history.
We at TABIIB would love to shed some light on how cervical cancer has evolved and how in certain cultures it is still seen beyond the mainstream.
Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570,000 women were diagnosed with cervical cancer worldwide and about 311,000 women died from the disease.
Although cervical cancer affects over half a million women 1,000,000; it’s a rare outcome of a prevalent infection. For most women who become infected, it’s a result of a cell-mediated immune response that occurs within months or years.
One of the most effective histories of medicine is the discovery and confirmation of human papillomavirus (HPV) essentially a cause of cervical cancer. The path to this point, however, is paved by fascinating vignettes of early conflicts between scientific disciplines.
The transient aspects of most HPV infections have been demonstrated over the last 2 decades by studies on the natural history of human papillomavirus (HPV). The significance of HPV persistence in invading cancer associated with HPV.
The benign nature of cervical intraepithelial neoplasia (CIN 1) has also been studied to prevent the progression to invasive cancer. It’s also done to demonstrate CIN 3’s value as a vital precancerous lesion or tumours requiring diagnosis and treatment.
Factors Associated With Cervical Cancer
Cofactors associated with cervical cancer include:
- smoking cigarettes
- excessive oral contraceptive use
- chlamydia infections
However, the contributions of these cofactors remain minuscule compared to the role of high-risk HPV persistence.
A history of cervical precancer increases the risk for other HPV-related neoplasms. From the earliest studies of HPV16 and 18 DNA in cervical cancer and cervical squamous intraepithelial lesions. It became clear that cervical testing for HPV could provide a valuable additional test in cervical cancer prevention for use in cervical screening and the management of screen-detected abnormalities.
With a lifetime risk of high-risk human papillomavirus infection around 80% and less than 1% of those infections leading to cervical cancer. The development of cervical carcinoma is a rare complication of hrHPV infection.
How Cervical Cancer Develops
Cervical cancer develops through a series of stages and takes years. The large majority of HPV lesions, however, are productive lesions that produce and shed viral particles without signs of cellular transformation. The morphology of HPV-induced lesions is such that it’s impossible to reliably distinguish which lesions are transforming to cancer from those with a high chance of spontaneous regression.
Scientists’ understanding of HPV disease explains many clinical observations and has clear implications for the development of diagnostic and therapeutic strategies. They’ve examined the molecular principles that lie behind current clinical approaches and draw attention to their relative merits and limitations.
Although most girls infected with the virus become negative within 2 years, women with persistent high-risk HPV infections are at the greatest risk for developing cervical cancer. Since the identification of HPV because of the necessary explanation for cervical cancer, HPV-based technology has become the centre of novel primary and secondary cervical cancer. Prevention strategies by the introduction of HPV testing in screening and of HPV vaccines in preadolescent girls and young women.
Most cases of cervical cancer can be avoided by successful primary (HPV) and secondary prevention methods (screening and treatment of precancerous lesions).
Cervical cancer is one of the most active types of cancer when diagnosed as long as it is early identified and effectively monitored. Appropriate care and palliative attention can also regulate cancers diagnosed in late stages.
Pitfalls In The Traditional Approach To Prevention
Worldwide efforts in the prevention of cervical cancer are concentrated on the diagnosis and treatment of women with precarious lesions at risk (Pap). In the light of the continuity and screening coverage, these measures have decreased by up to 90% the invasion rate of cervical cancer.
Many developing countries were, however, still unable to incorporate robust Pap smear screening programs. The only limited number of women, particularly through maternal, child and family planning clinics can be reached by private health providers and young women in countries with Pap smear screening.
One of the most critical obstacles for cancer initiatives is to promote preventive services for women at the highest risk of treatable precancers, mostly in their 30s and 40s. Because many women in this age group have completed childcare and therefore are unable to access family planning or maternal health services, special approaches are important to notify them of the need for screening and availability.
The best ways to raise awareness in women who have spent their reproductive years are to be built from the awareness women can create towards this disease. Cervical cancer can only be eliminated within a century as a public health issue with a systematic approach to prevention, screening, and care.